Rose Du1, Jing Zhou2, Svetlana Lorenzano2, Wenming Liu2, Nareerat Charoenvimolphan2, Baogang Qian2, Jun Xu2, Jian Wang2, Xinmu Zhang2, Xin Wang2, Annerose Berndt2, William J Devan2, Valerie J Valant2, Jinyi Wang2, Karen L Furie2, Jonathan Rosand2, Natalia Rost2, Robert M Friedlander2, Beverly Paigen2, Scott T Weiss2. 1. From the Department of Neurosurgery (R.D., J.Z., W.L., N.C., B.Q., J.X., J.W., X.Z., X.W.) and Channing Division of Network Medicine, Department of Medicine (R.D., S.T.W.), Brigham and Women's Hospital, Boston, MA; Department of Neurology, Massachusetts General Hospital, Boston (S.L., W.J.D., V.J.V., J.R., N.R.); Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy (S.L.); Department of Chemical Biology, Northwest Agriculture and Forestry University, Shaanxi, People's Republic of China (W.L., J.W.); Department of Neurosurgery, China-Japan Friendship Hospital, Beijing, People's Republic of China (J.X.); The Jackson Laboratory, Bar Harbor, ME (A.B., B.P.); Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine (A.B.) and Department of Neurosurgery (R.M.F.), University of Pittsburgh School of Medicine, PA; Quinnipiac University Frank H. Netter, MD School of Medicine, Hamden, CT (W.J.D.); University of Massachusetts Medical School, Worcester (V.J.V.); and Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI (K.L.F.). rdu@partners.org. 2. From the Department of Neurosurgery (R.D., J.Z., W.L., N.C., B.Q., J.X., J.W., X.Z., X.W.) and Channing Division of Network Medicine, Department of Medicine (R.D., S.T.W.), Brigham and Women's Hospital, Boston, MA; Department of Neurology, Massachusetts General Hospital, Boston (S.L., W.J.D., V.J.V., J.R., N.R.); Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy (S.L.); Department of Chemical Biology, Northwest Agriculture and Forestry University, Shaanxi, People's Republic of China (W.L., J.W.); Department of Neurosurgery, China-Japan Friendship Hospital, Beijing, People's Republic of China (J.X.); The Jackson Laboratory, Bar Harbor, ME (A.B., B.P.); Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine (A.B.) and Department of Neurosurgery (R.M.F.), University of Pittsburgh School of Medicine, PA; Quinnipiac University Frank H. Netter, MD School of Medicine, Hamden, CT (W.J.D.); University of Massachusetts Medical School, Worcester (V.J.V.); and Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI (K.L.F.).
Abstract
BACKGROUND AND PURPOSE: The extent of ischemic injury in response to cerebral ischemia is known to be affected by native vasculature. However, the nonvascular and dynamic vascular responses and their genetic basis are not well understood. METHODS: We performed a genome-wide association study in 235 mice from 33 inbred strains using the middle cerebral artery occlusion model. Population structure and genetic relatedness were accounted for using the efficient mixed-model association method. Human orthologs to the genes associated with the significant and suggestive single-nucleotide polymorphisms from the mouse strain survey were examined in patients with M1 occlusions admitted with signs and symptoms of acute ischemic stroke. RESULTS: We identified 4 genome-wide significant and suggestive single-nucleotide polymorphisms to be associated with infarct volume in mice (rs3694965, P=2.17×10(-7); rs31924033, P=5.61×10(-6); rs32249495, P=2.08×10(-7); and rs3677406, P=9.56×10(-6)). rs32249495, which corresponds to angiopoietin-1 (ANGPT1), was also significant in the recessive model in humans, whereas rs1944577, which corresponds to ZBTB7C, was nominally significant in both the additive and dominant genetic models in humans. ZBTB7C was shown to be upregulated in endothelial cells using both in vitro and in vivo models of ischemia. CONCLUSIONS: Genetic variations of ANGPT1 and ZBTB7C are associated with increased infarct size in both mice and humans. ZBTB7C may modulate the ischemic response via neuronal apoptosis and dynamic collateralization and, in addition to ANGPT1, may serve as potential novel targets for treatments of cerebral ischemia.
BACKGROUND AND PURPOSE: The extent of ischemic injury in response to cerebral ischemia is known to be affected by native vasculature. However, the nonvascular and dynamic vascular responses and their genetic basis are not well understood. METHODS: We performed a genome-wide association study in 235 mice from 33 inbred strains using the middle cerebral artery occlusion model. Population structure and genetic relatedness were accounted for using the efficient mixed-model association method. Human orthologs to the genes associated with the significant and suggestive single-nucleotide polymorphisms from the mouse strain survey were examined in patients with M1 occlusions admitted with signs and symptoms of acute ischemic stroke. RESULTS: We identified 4 genome-wide significant and suggestive single-nucleotide polymorphisms to be associated with infarct volume in mice (rs3694965, P=2.17×10(-7); rs31924033, P=5.61×10(-6); rs32249495, P=2.08×10(-7); and rs3677406, P=9.56×10(-6)). rs32249495, which corresponds to angiopoietin-1 (ANGPT1), was also significant in the recessive model in humans, whereas rs1944577, which corresponds to ZBTB7C, was nominally significant in both the additive and dominant genetic models in humans. ZBTB7C was shown to be upregulated in endothelial cells using both in vitro and in vivo models of ischemia. CONCLUSIONS: Genetic variations of ANGPT1 and ZBTB7C are associated with increased infarct size in both mice and humans. ZBTB7C may modulate the ischemic response via neuronal apoptosis and dynamic collateralization and, in addition to ANGPT1, may serve as potential novel targets for treatments of cerebral ischemia.
Authors: Matthew J McGirt; John R Lynch; Augusto Parra; Huaxin Sheng; Robert D Pearlstein; Daniel T Laskowitz; Dale A Pelligrino; David S Warner Journal: Stroke Date: 2002-12 Impact factor: 7.914
Authors: Samuel Valable; Joan Montaner; Anita Bellail; Vincent Berezowski; Julien Brillault; Romeo Cecchelli; Didier Divoux; Eric T Mackenzie; Myriam Bernaudin; Simon Roussel; Edwige Petit Journal: J Cereb Blood Flow Metab Date: 2005-11 Impact factor: 6.200
Authors: M E Gurol; M C Irizarry; E E Smith; S Raju; R Diaz-Arrastia; T Bottiglieri; J Rosand; J H Growdon; S M Greenberg Journal: Neurology Date: 2006-01-10 Impact factor: 9.910
Authors: Stephen R Williams; Qiong Yang; Fang Chen; Xuan Liu; Keith L Keene; Paul Jacques; Wei-Min Chen; Galit Weinstein; Fang-Chi Hsu; Alexa Beiser; Liewei Wang; Ebony Bookman; Kimberly F Doheny; Philip A Wolf; Michelle Zilka; Jacob Selhub; Sarah Nelson; Stephanie M Gogarten; Bradford B Worrall; Sudha Seshadri; Michèle M Sale Journal: PLoS Genet Date: 2014-03-20 Impact factor: 5.917
Authors: Joseph V Moxon; Alexandra F Trollope; Brittany Dewdney; Catherine de Hollander; Domenico R Nastasi; Jane M Maguire; Jonathan Golledge Journal: J Cereb Blood Flow Metab Date: 2019-10-04 Impact factor: 6.200
Authors: Alexander I Kostyuk; Aleksandra D Kokova; Oleg V Podgorny; Ilya V Kelmanson; Elena S Fetisova; Vsevolod V Belousov; Dmitry S Bilan Journal: Antioxidants (Basel) Date: 2020-06-11
Authors: Robert F Rudy; Nareerat Charoenvimolphan; Baogang Qian; Annerose Berndt; Robert M Friedlander; Scott T Weiss; Rose Du Journal: Sci Rep Date: 2019-03-25 Impact factor: 4.379
Authors: Dongjing Liu; Annie I Arockiaraj; John R Shaffer; Samuel M Poloyac; Paula R Sherwood; Sheila A Alexander; Elizabeth A Crago; Daniel E Weeks; Yvette P Conley Journal: Epigenetics Commun Date: 2021-12-20
Authors: Dmitry Prokopenko; Julian Hecker; Rory Kirchner; Brad A Chapman; Oliver Hoffman; Kristina Mullin; Winston Hide; Lars Bertram; Nan Laird; Dawn L DeMeo; Christoph Lange; Rudolph E Tanzi Journal: Sci Rep Date: 2020-03-19 Impact factor: 4.379